NALIRIFOX Versus FOLFOX as First-oLine Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC): Real-World Comparative Overall (OS) Survival Analysis

被引：0

作者：

O'Reilly, Eileen ^{[1
]}

Li, Jia ^{[2
]}

DerSarkissian, Maral ^{[3
]}

Chang, Rose ^{[4
]}

Cheng, Mu ^{[4
]}

Yu, Louise ^{[4
]}

Rane, Deepali ^{[2
]}

Zhang, Li ^{[2
]}

Xiao, Zhimin ^{[2
]}

Benzaghou, Fawzi ^{[5
]}

Duh, Mei Sheng ^{[4
]}

Chen, Huanyu ^{[2
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Ipsen Corp, Paris, France

[3] Anal Grp Inc, Los Angeles, CA USA

[4] Anal Grp Inc, Boston, MA USA

[5] IPSEN, Paris, France

来源：

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2024年 / 33卷

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

442

引用

页码：176 / 176

页数：1

共 50 条

[1] NALIRIFOX (iposomal irinotecan+5-fluorouracil/feucovorin plus oxaliplatin) versus FOLFOX [5-fluorouracil/leucovorin plus oxaliplatin] as first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): Real-world comparative overall survival
O'Reilly, E.
Li, J.
DerSarkissian, M.
Chang, R.
Cheng, M.
Yu, L.
Rane, D.
Zhang, L.
Xiao, Z.
Benzaghou, F.
Duh, M.
Chen, H.
ANNALS OF ONCOLOGY, 2023, 34 : S83 - S83
[2] Effect of dose adjustments on overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX: A post hoc analysis of NAPOLI 3
Patel, Anjan J.
Laursen, Ashley Ann
Cockrum, Paul
Liu, Yutong
Surinach, Andy
Rhodes, Whitney
Zhang, Li
Li, Jia
Maxwell, Fiona
Wainberg, Zev A.
O'Reilly, Eileen M.
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 716 - 716
[3] Real-world overall survival of patients diagnosed with recurrent versus de novo metastatic pancreatic ductal adenocarcinoma (PDAC).
O'Reilly, Eileen Mary
Yu, Kenneth H.
Lamarre, Neil
Surinach, Andy
Cockrum, Paul
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[4] Dosing patterns and treatment patterns in real-world patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first line
MacEwan, Joanna P.
Silver, Michelle
Cockrum, Paul
Sanders, Chad
Kim, George P.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[5] Real-world patterns of pain medication use among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
Laursen, Ashley Ann
Surinach, Andy
Wang, Shu
Cockrum, Paul
George, Ben
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
[6] Population-based, real-world prognostic factors related to survival among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
Yu, Kenneth H.
Cockrum, Paul
Surinach, Andy
Wang Shu
Chu, Bong Chul
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[7] Assessing real-world survival outcomes of patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with first-line FOLFIRINOX compared to patients from a phase 1/2 trial treated with NALIRIFOX.
Zhu, Xuelian
Cockrum, Paul
Shah, Bonny
Parzynski, Craig
Garawin, Tamer
Maxwell, Fiona
Surinach, Andy
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[8] Overall survival (OS) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with first-line (1L) FOLFIRINOX (FFX): Bridging the gap between the NAPOLI 3 trial and real-world practice.
Cockrum, Paul
Chang, Rose
Yu, Louise Huafeng
Xu, Chunyi
Duh, Mei Sheng
Kim, George P.
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
[9] Real-world overall survival and time to next treatment in patients with metastatic pancreatic ductal adenocarcinoma who received FOLFIRINOX and modified FOLFIRINOX in the first line.
Dennen, Syvart
Boppudi Naga, Sai Sriteja
Cockrum, Paul
Paluri, Ravi Kumar
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 629 - 629
[10] PREDICTORS OF OVERALL SURVIVAL (OS) AND TIME TO NEXT TREATMENT (TTNT) IN REAL-WORLD METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (mPDAC) PATIENTS WHO RECEIVED FIRST-LINE (1L) FOLFIRINOX (FFX) OR GEMCITABINE plus NAB-PACLITAXEL (GnP)
Dennen, S.
Silver, M.
Cockrum, P.
Kim, G. P.
VALUE IN HEALTH, 2024, 27 (06) : S22 - S22

← 1 2 3 4 5 →